Summary of Key Points Core Viewpoint - The report outlines the non-operating fund occupation and other related fund transactions of Innovation Medical Management Co., Ltd. for the first half of 2025, detailing the amounts involved and the nature of these transactions [1]. Group 1: Non-Operating Fund Occupation - The total non-operating fund occupation at the beginning of 2025 was 33,630.47 thousand yuan, with an additional 996.48 thousand yuan occupied in the first half of the year, leading to a cumulative occupation of 1,000.00 thousand yuan [2]. - The report specifies that the funds were primarily occupied by the controlling shareholders, actual controllers, and their affiliated enterprises [2]. - The reasons for the fund occupation include non-operating transactions, with specific amounts listed for various subsidiaries [2]. Group 2: Related Fund Transactions - The total related fund transactions at the beginning of 2025 amounted to 33,630.47 thousand yuan, with 996.48 thousand yuan occurring in the first half of the year, resulting in a cumulative transaction amount of 1,000.00 thousand yuan [2]. - The transactions are categorized as non-operating, with specific subsidiaries listed, such as Qiqihar Jianhua Hospital Co., Ltd. and Jiangsu Futian Rehabilitation Hospital Co., Ltd., detailing their respective amounts and reasons for the transactions [2]. - The report indicates that these transactions are primarily recorded under "other receivables" in the accounting records [2].

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth in the A-share market, with the BCI index reaching a historical high, indicating a promising future for the industry [2][3]. Industry Overview - The BCI technology is seen as a new frontier, with applications in medical fields such as disease warning, diagnosis, treatment, and functional enhancement, as well as in non-medical sectors like consumer and industrial applications [5][6]. - The global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040, highlighting the substantial growth potential in this sector [5]. Company Developments - Several companies, including Sainuo Medical, Guangdian Co., and Shangrong Medical, have seen their stock prices surge, with multiple stocks hitting the daily limit up [3]. - Companies like Lide Man and Botuo Bio have reported significant gains, with Lide Man increasing over 11% and Botuo Bio rising by 10% [3]. - Sanbo Brain Science has completed an interventional BCI trial, showcasing China's innovation capabilities in this field and marking a significant step in treating movement disorders [3]. Strategic Initiatives - Chengyitong has established a dual-track strategy focusing on both invasive and non-invasive BCI technologies, aiming to integrate existing rehabilitation devices with BCI [4]. - Yanshan Technology's subsidiary has developed a brain-computer interface system that has demonstrated excellent performance in clinical trials, indicating advancements in the technology [5]. Policy Support - The Chinese government has been actively promoting the BCI industry through various policies, with multiple regions releasing action plans to accelerate development [6]. - The Ministry of Industry and Information Technology has outlined goals for the BCI sector over the next five years, aiming for breakthroughs in key technologies and the establishment of a robust industrial ecosystem by 2030 [6][7]. Market Challenges and Opportunities - The BCI industry faces challenges in making technology affordable for the general public, with current rehabilitation robots costing around 1 million yuan, which is still considered expensive [7][8]. - The integration of BCI technologies into medical insurance reimbursement lists is seen as a critical step for commercial viability and wider adoption [8].

Core Viewpoint - The brain-computer interface (BCI) industry is expected to experience significant growth, with 2023 being a pivotal year for its development and application across various sectors [2][8]. Group 1: Market Performance - The BCI concept stocks have seen a strong rally, with several companies like Sainuo Medical, Guangdian Co., and Shangrong Medical hitting their daily price limits [4]. - Notable stock performances include Lide Man and Botuo Bio, which rose over 11%, and Meilan De, which increased by 10% [4]. Group 2: Technological Advancements - BCI technology connects the brain with external devices for information exchange, showing promise in medical fields such as disease diagnosis and treatment [6]. - Significant advancements have been made in BCI technology, particularly in biomedical applications, neuro-rehabilitation, and intelligent robotics [6]. Group 3: Industry Outlook - According to McKinsey, the global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040 [7]. - The Chinese BCI industry, although starting late, is rapidly developing, with multiple policies introduced since 2025 to support its growth [9][10]. Group 4: Policy Support - Recent government initiatives aim to accelerate the commercialization of BCI technology, with specific action plans released by cities like Beijing and Shanghai [9][10]. - The Ministry of Industry and Information Technology and other departments have set ambitious goals for the BCI industry over the next five years, focusing on technological breakthroughs and establishing a robust industrial ecosystem [10]. Group 5: Application Areas - The BCI industry has two primary application areas: serious medical applications, such as rehabilitation for stroke and spinal injury patients, and consumer applications addressing issues like sleep disorders [11]. - A significant challenge for the industry is to reduce costs, making BCI technologies more accessible to the general public [11][12].

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净齿比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-08 | 17.60 0.74% | | -1.65 Z | -5.06% | -5124.16万 | -1.57% | 2.16/Z | 6.63% | | 2025-08-07 | 17.47 10.01% | | 1.884Z | 9.15% | -1.20 乙 | -5.84% | -6795.37万 | -3.32% | | 2025-08-06 | 15.88 | -2.16% | -1.65亿 | -9.77% | -4099.22万 | -2.43% | 2.06亿 | 12.20% | | 2025-08-05 | | 16.23 10.03% | 4.65 Z | 28.40% | -2.26亿 | -13.78% | -2.39 Z | -14.62% | | 2025-08-04 | 14.75 | -1.14% | -5869.00万 ...

创新医疗2025半年报 ...

（文章来源：北京商报） 北京商报讯（记者丁宁）8月8日晚间，创新医疗（002173）披露2025年半年报显示，公司上半年实现营 业收入4.02亿元，同比下降1.6%；归属净利润为-1136.13万元，同比出现减亏。 创新医疗表示，公司营业收入及利润主要来源于医疗服务。与去年同期相比，本期得益于医保回款同比 增长引起信用减值损失同比下降等原因，公司亏损同比有所收窄。 ...

风险提示：投资有风险，入市需谨慎。 来源：金融界 公司8月8日披露的半年报显示，上半年实现营业收入4.02亿元，同比下降1.60%；归母净利润亏损 1136.13万元，较上年同期亏损1602.96万元有所收窄。第二季度，公司实现归母净利润258万元，成功扭 亏。 8月8日，创新医疗主力资金净流出1.65亿元，占流通市值的2.25%。近五个交易日，主力资金累计净流 入2.64亿元，占流通市值的3.61%。 截至2025年8月8日15时，创新医疗股价报17.60元，较前一交易日上涨0.74%。当日开盘价为19.22元， 最高触及19.22元，最低下探至17.55元，成交量为172.44万手，成交额达32.55亿元。 创新医疗属于医疗服务行业，公司旗下拥有建华医院、康华医院、福恬医院和明珠医院四家医疗机构。 其中，建华医院为三级甲等综合性医院，康华医院和明珠医院为二级甲等综合性医院，福恬医院为二级 康复医院。 ...

每经AI快讯，创新医疗8月8日披露半年报，公司上半年实现营业收入4.02亿元，同比下降1.60%；归属 于上市公司股东的净利润亏损1136.13万元，上年同期亏损1602.96万元；基本每股收益-0.03元。 （文章来源：每日经济新闻） ...

创新医疗管理股份有限公司 2025 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：陈海军 主管会计工作负责人：杨建荣 会计机构负责人（会计主管人员）：杨建荣 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算 | 2025 年期初占用 | | 2025 年半年度占用累计 | | 2025 年半年度占用 | 2025 | 年半年度偿 | 2025 年半年度期 | | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 的会计科目 | 资金余额 | | 发生金额（不含利息） | | 资金的利息(如有) | 还累计发生金额 | | 末占用资金余额 | | 原因 | | | 控股股东、实际控制人及 | | | | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | | | | | 小计 | | | | | | | | | | ...

创新医疗管理股份有限公司 2025 年半年度财务报告 创新医疗管理股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 2025 年 8 月 1 创新医疗管理股份有限公司 2025 年半年度财务报告 财务报告 编制单位：创新医疗管理股份有限公司 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 249,045,212.83 | 137,984,131.56 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 213,134,328.80 | 287,799,259.39 | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 74,886,592.50 | 124,184,225.79 | | 应收款项融资 | | | | 预付款项 | 4,227,450.08 | 4,649,527.59 | | 应收保费 | | | | 应收分保账款 | | ...